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Abstract
Purpose—Local and distant failure rates remain high despite aggressive chemoradiation (CRT)
treatment for stage III non-small cell lung cancer (NSCLC). We conducted preclinical studies of
docetaxel cytotoxic and radiosensitizing effects on lung cancer cell lines and designed a pilot
study to target distant micrometastasis upfront with one-cycle induction chemotherapy, followed
by low-dose radiosensitizing docetaxel CRT.
Methods and Materials—Preclinical study was conducted in human lung cancer cell lines NCI
520 and A549. Cells were treated with two concentrations of docetaxel for 3 hours and then
irradiated immediately vs. delayed at 24 hours. Clonogenic survival assay was conducted and
analyzed for cytotoxic effects vs. radiosensitizing effects of docetaxel. A pilot clinical study was
designed based on pre-clinical study findings. Twenty-two patients were enrolled with a median
follow-up of 4 years. Induction chemotherapy consisted of 75 mg/m2 docetaxel and 75 mg/m2
cisplatin on day 1, and rh-GCSF 150 mg/m2 on days 2–10. Concurrent CRT started 3–6 weeks
later with twice-weekly docetaxel at 10–12 mg/m2 and daily delayed radiation in 1.8 Gy fractions
to 64.5 Gy for gross disease.
Results—Preclinical study demonstrated potent cytotoxic effects of docetaxel and subadditive
radiosensitizing effects. Delaying radiation resulted in more cancer cell death. The pilot clinical
study resulted in a median survival of 32.6 months for the entire cohort, with a 3-year and 5-year
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survival of 50% and 19%, respectively, and a distant metastasis-free survival rate of 61% for both
3 and 5 years. Patterns of failure analysis revealed 75% chest failures, and 36% all distant failures.
Therapy was well tolerated with grade 3 esophagitis observed in 23% of patients.
Conclusions—One-cycle full-dose docetaxel/cisplatin induction chemotherapy with rh-GCSF
followed by pulsed low-dose docetaxel chemoradiation is promising in its anti-tumor activity, low
rates of distant failure, and low toxicity, suggesting that this regimen deserves further
investigation.
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INTRODUCTION
Locally advanced stage III non-small cell lung cancer (NSCLC) has often been considered
unresectable. Definitive radiation in combination with chemotherapy, either sequentially or
concomitantly, has been reported to yield favorable survival outcome over radiation alone in
several phase III studies. However, this result is associated with a disappointingly high rate
of intrathoracic failure as well as distant metastasis. The median survival rate has been in the
range of 11– 16 months in most large studies, with a 5-year survival rate at 6–20% (1–9).
The intrathoracic failure rate is quite high, which is approximately 50% by radiographic
criteria, and more than 85% by biopsy through bronchoscopy, with the distant failure rate
being more than 70% (1,4,5,7).
Findings from two of the phase III studies support that concurrent CRT is superior to
sequential CRT. The study by Radiotherapy Oncology Group (RTOG) revealed a median
survival of 17.1 months in the CRT arm vs. 14.6 months in the sequential (2), while the
Western Japan study showed a median survival of 17 months vs. 13 months respectively
(2,4). Combining two modalities concurrently results in better survival but at the price of
more grade 3 toxicities, especially the increased risk of pneumonitis and esophagitis (1–9).
Therefore, using low-dose sensitizing chemotherapy during CRT may offer clinical
advantages without increasing adverse side effects.
Taxanes are known for the cytotoxic effects and radiosensitizing effects. In a preclinical
study, we investigated the cell cycle effects of both paclitaxel and docetaxel for radiation
sensitization of lung cancer cell lines. Docetaxel demonstrated a G2/M arrest for 72–96
hours while paclitaxel sustained a G2/M arrest for 48 hours of lung cancer cell lines.
Docetaxel also demonstrated better subadditive effects with radiation when compared with
paclitaxel in preclinical investigations (12,13). Subsequently, a clinical phase I/II study was
conducted using a pulsed low-dose paclitaxel radiosensitizing strategy with paclitaxel
dosing once every 48 hours, which yielded a 97.6% in-field chest tumor control rate
(10,11,14). However, the low-dose pulsed paclitaxel chemoradiation did not appear to
further improve the survival result when compared with other large randomized studies
using full-dose chemotherapy and radiation. Thus, a therapeutic strategy that will integrate
full-dose chemotherapy in combination with low-dose sensitizing chemoradiation is
desirable in targeting micrometastasis and in reducing treatment-related toxicities for better
chest disease control.
Based upon the superior local tumor effect of radiosensitization by pulsed low-dose
paclitaxel, we designed a pilot study for the treatment of stage IIIA and IIIB NSCLC, using
one-cycle induction chemotherapy consisting of docetaxel and cisplatin followed by pulsed
low-dose sensitizing docetaxel chemoradiotherapy for gross chest tumors. The rationale of
using one-cycle induction chemotherapy instead of the conventional 2 to 3 cycles is based
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on the hypothesis that delaying local therapy to gross chest disease is detrimental to cancer
control (15,16), and that a single cycle of full-dose chemotherapy should suffice in targeting
systemic micrometastasis at the beginning of cancer therapy without further delaying local
therapy.
MATERIALS AND METHODS
Preclinical study of radiation and docetaxel interactions
Human lung cancer cell lines NCI 520 and A549 were used. Because p53 status may affect
radiation sensitivity, the p53 status of these cancer cell lines was assayed in the laboratory
and both cell lines were found to have normal p53 status. All cells were grown as monolayer
cultures in Eagle Minimum Essential Medium (EMEM) (Life Technologies, Inc.
Laboratories. Grand Island, NY) supplemented with 10% fetal bovine serum (Life
Technologies, Inc. Laboratories) and 100 units/ml penicillin and streptomycin (Life
Technologies, Inc. Laboratories). All cell culture experiments were carried out at 37°C in a
humidified 5% CO2 environment. The cell cultures were initiated with 5 × 105 exponentially
growing cells in 75-cm2 flakes (Corning Glass Works, Corning, NY) for 2–3 days.
Radiation effect and interaction with docetaxel treatment were conducted using the
clonogenic survival assay in monolayer cell cultures. For drug treatments, cells were
incubated with two concentrations of docetaxel (25 nM vs. 50 nM for A549, and 50 nM vs.
100 nM for NCI 520) for 3 hours. After drug treatments, the cells were washed with EMEM
3 times and supplemented with 10% fetal bovine serum and 100 units/ml penicillin and
streptomycin. Cell cultures were then separated into the early radiation group (3 hours) vs.
the delayed radiation group (24 hours) at room temperature (20°C ± 1.5°C) using a
Cesium-137 gamma-ray irradiator at a dose rate of 4 Gy per minute. The radiation doses
were 2, 6, 8, and 10 Gy in single fractions. Cells were trypsinized after irradiation and plated
at different dilutions in 60 mm petri dishes for two weeks for colony-forming measurement.
The cell-surviving fraction was determined from the ratio of colony-forming efficiency of
irradiated cells to non-irradiated control. The average surviving fraction at each dose was
determined from at least three replicated experiments. Survival curves were constructed by
plotting the surviving fraction as a function of dose according to the linear quadratic model,
S = exp (−aD−βD2), and the multi-target model using least-squares regression and linear
regression, respectively.
Patient eligibility and pretreatment evaluation
This study was fully reviewed and approved by the University of Rochester Institutional
Review Board. Table 1 shows the characteristics of patients enrolled in the protocol.
Twenty-two patients, with a median age of 62, were enrolled from February 2002 to April
2005. Patients were informed of the investigational nature of this study and gave written
informed consent in accordance with institutional and federal guidelines. Patients with
proven histological stage IIIa and IIIb NSCLC were eligible for this study, and were staged
according the American Joint Committee on Cancer (AJCC). The eligibility criteria included
the following: Age ≥ 18, Karnofsky performance status ≥ 70%, forced expiratory volume in
1 second (FEV 1) ≥ 800 ml, and serum creatinine ≤ 1.5 mg/dl or creatinine clearance > 60
ml/min. Patients with hypersensitivity to docetaxel, myocardial infarction or symptomatic
heart disease (including angina, congestive heart failure, uncontrolled arrhythmia) within the
previous 6 months were excluded, along with patients with malignant pleural effusion and
women who were pregnant or breastfeeding.
Pretreatment evaluation included a detailed medical history, physical examination, and
performance status. Blood work included a Complete Blood Count with differential, platelet
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count, electrolytes, serum glutamic pyruvic transaminase (SGPT), total protein, albumin,
calcium, inorganic phosphorus, glucose, blood urea nitrogen (BUN), uric acid, creatinine,
alkaline phosphatase, lactate dehydrogenase (LDH), total bilirubin, and serum glutamic
oxaloacetic transaminase (SGOT). Creatinine clearance was required if serum creatinine was
>1.5 mg/dl. Chest X-ray and computerized tomography (CT) scans of the chest (including
liver and adrenal glands) were done within 4–6 weeks of registration. CT scans of the brain
and either a positron emission tomography (PET) or a radionuclide bone scan were required
to rule out distant metastasis. Electrocardiogram (EKG) and pulmonary function tests
including FEV1, vital capacity (VC), and diffusion lung capacity for carbon monoxide
(DLCO) were required.
Protocol treatment
Beginning 24 hours before docetaxel, patients were given 8 mg dexamethasone orally twice
daily for 3 days. A 16 mg dose of ondansetron was administered intravenously before
treatment, and 8 mg twice daily was taken orally for 3 days following treatment. All patients
received one cycle of induction chemotherapy consisting of docetaxel 75 mg/m2 and
cisplatin 75 mg/m2 on day 1 given sequentially over a one hour IV infusion, and rh-GCSF
150 mg/m2 on days 2–10. Cisplatin infusion was given according to the University of
Rochester’s institutional policy of hydration and diuresis. Patients received 2 liters of normal
saline with added potassium. Magnesium was given separately. Polyantiemetics were given
on day 1. After cisplatin infusion, an additional 1000 ml of hydration fluid was given over 2
hours. For 12 hours afterward, inpatients were given an additional 2 liters of fluid
intravenously, while outpatients were encouraged to drink as much liquid as possible
overnight.
Concurrent chemoradiation started 3– 6 weeks after the induction chemotherapy. Given the
longer duration of G2/M effect up to 72–96 hours by docetaxel in the preclinical
investigation of lung cancer cell lines, sensitizing docetaxel at 12 mg/m2 was delivered on
Monday and Thursday mornings, with IV over 15–30 minute infusion, and daily radiation.
The dose of 12 mg/m2 docetaxel twice weekly was chosen based on the maximum tolerated
dose of twice weekly dosing previously reported at 15 mg/m2 (17), but subsequently was
reduced to 10 mg/m2 due to the high rate of grade 3 esophagitis. Concurrent chemoradiation
schema is shown in Table 2. At least a 4 hour delayed RT interval was required between RT
and docetaxel to allow for progression to the G2/M phase, the most radiosensitive phase of
the cell cycle. Patients were given 10 mg dexamethasone IV prior to the low-dose docetaxel.
One 150 mg dose of ranitidine daily during concurrent chemoradiation was recommended.
Radiation therapy
Radiation treatment was delivered using conformal CT guided radiation plans. Gross disease
was defined as visible primary disease and enlarged lymph nodes (≥ 1 cm) on CT scans.
Microscopic disease was defined as no grossly visible mediastinal and supraclavicular
lymph nodes on CT scans. The radiation portal included the gross disease and prophylactic
mediastinal radiation. Radiation therapy began on the Tuesday after the first dose of
sensitizing docetaxel given on Monday. Treatment volume included the gross disease with a
2 cm margin. All gross disease received 60–65 Gy. Regional lymphatics with potential
microscopic disease received 45–58 Gy. Daily fraction was 1.8 Gy. Contralateral hilum was
not included unless it was suspicious for disease involvement (N3) on CT scan or pathologic
documentation. The spinal cord dose was kept below 50 Gy. Supraclavicular region(s) were
treated prophylactically for microscopic disease for upper lobe lesions or high mediastinal
nodal involvement. The total dose to the supraclavicular fosse did not exceed 50.4 Gy for
microscopic disease. For grossly enlarged supraclavicular fossa lymph nodes, electron boost
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after 50.4 Gy to the final dose of 60 Gy was allowed. An example of the radiation plan is
shown in Figure 1.
Chemotherapy dose modifications
There was dose modification in the induction phase as there was only one cycle. The
sensitizing docetaxel dose was reduced to 10 mg/m2 after the tenth enrolled patient because
of the high incidence of grade 3 dysphagia or esophagitis.
Evaluation of toxicity and response
All treated patients were followed at 6–8 weeks post therapy and then once every 3 months
in the first two years, once every 6 months from year 3 to year 5, and once a year after the
5th year. Physical examinations, vital signs and a chest CT scans were done at each follow-
up visit. Toxicity was assessed by the Common Terminology Criteria for Adverse Events
v3.0 (CTCAE) by National Cancer Institute (NCI). Response to therapy by CT scan was
assessed according to 2D radiological tumor measurements by the following criteria:
complete Response (CR) - complete disappearance of all tumor evidence; partial Response -
at least 50% of measured area; stable Disease (SD) – stable disease; progressive Disease
(PD) - development of any new areas of malignant disease that were measurable or palpable,
or by a ≥ 25% increase in any pretreatment area of measurable disease.
Statistical analyses
Overall survival, progression-free survival, and distant metastasis-free survival were
calculated using the Kaplan-Meier life table methods. Disease recurrence was defined as the
time between the first day of therapy until the first notation of clinical progression or
relapse. The time of survival was defined as time from treatment start to death or last date
known alive.
RESULTS
Radiation and docetaxel interaction in lung cancer cell lines
Figure 2 shows the clonogenic survival of human lung cancer cell lines NCI 520 and A549
after irradiation at 2, 4, 6, and 8 Gy with sham irradiation. For both cell lines, there was a
marked decrease of surviving lung cancer cell fractions after docetaxel treatment by more
than one log as shown on Y-axis comparing control and drug treated groups at 0 Gy
radiation (Figure 2). This reduction of surviving fractions was directly attributed to cytotoxic
effects of docetaxel on lung cancer cells without radiation effects. When comparing the
controls and drug treated groups in response to increasing radiation doses, there was an
additional reduction of surviving fractions with increasing radiation doses for all, although
in some cases the slope of the curves in the drug treated groups appeared shallower than the
control. Despite such observations, the surviving fractions of drug treated groups were much
less than the control, thus consistent with a subadditive effect of docetaxel and radiation
rather than a synergistic effect.
In the A549 cell line, the delayed radiation treatment groups (24 hours) resulted in more cell
death than immediate radiation (3 hours) in both the 25 nM and the 50 nM docetaxel
concentration groups. Likewise, for NCI-520 cell line, the delayed radiation groups resulted
in more cell death for both the 50 nM docetaxel group and the 100 nM docetaxel group.
Delaying radiation after drug treatment appeared to be the preferred strategy to enhance
radiation cytotoxicity, and therefore this observation was integrated into the timing of
radiation of this phase II clinical trial.
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Overall response rate was 69% [50% (11/22) PR and 19% (4/22) CR]. Of the 22 patients
enrolled in the study, 6 received partial protocol treatment for the following reasons: 4 of the
6 received the induction chemotherapy without subsequent CRT due to hypersensitivity
reactions to docetaxel (acute flushing, increased heart rate, and grade 3 hypoxia),
intermittent condition, or progressive disease. Two of the 6 completed induction
chemotherapy and initiated concurrent CRT but did not complete the latter due to
progressive disease in one and progressive intolerance to docetaxel during CRT in the other.
Treatment toxicity
Grade 3 and 4 toxicities are listed in Table 3. There was no grade 3 or 4 neutropenia, which
is likely due to the built-in rh-GCSF injection in the protocol. Five patients had grade 3
infections without neutropenia (4 had pneumonia and 1 had a groin infection).
Chemotherapy-related nausea/vomiting was observed in 6 patients. Esophagitis/dysphagia
was observed in 5 patients during chemoradiotherapy. Other grade 3 toxicities were fatigue
(4/22), loss of appetite (4/22), dyspnea/chest pain (2/22), lymphocytopenia (13/22), and
allergic reactions (2/22). One patient had grade 4 headaches, and one had grade 4 bone pain
due to the neupogen injection. There was one grade 4 AV heart block due to a change in
blood pressure medication as well as a previously undiagnosed cardiac condition.
Patterns of failure
We have analyzed the pattern of failure of patients treated in the protocol with a minimum
of follow up of 4 years: 45% failure in the radiation ports, 75% all chest failures, and 36%
all distant failures which included 23% brain failures.
Survival outcome
Figure 3 shows the Kaplan-Meier survival outcome for all patients enrolled. The 3-year and
5-year overall survival rate was 50% and 19%, respectively. The progressions -free survival
rate at 3 and 5 years was the same at 23%. The distant metastasis-free survival rate was 61%
for both 3 and 5 years.
DISCUSSION
A regimen that can improve both local disease control and reduce distant metastasis is
necessary to overcome the dismal outcome of inoperable NSCLC. Two different
mechanisms can contribute to the improvement of survival of patients from chemoradiation
treatment over radiation alone for locally advanced NSCLC. One is the potential cytotoxic
effect of chemotherapeutic agents in targeting distant subclinical micrometastasis. The other
is the radiosensitization effect of chemotherapy in improving the locoregional disease
control by sensitizing radiation effects, thereby controlling the primary source for distant
cancer spread. The randomized phase III study by the European Organization for Research
and Treatment of Cancer (EORTC) employing weekly low-dose cisplatin (30 mg/m2 per
week) or very low daily dose cisplatin (6 mg/m2 per day) resulted in a significant
improvement of survival in stage III NSCLC compared to radiotherapy alone (9). Such low
does of chemotherapy are not expected to render significant cytotoxic effects on cancer
cells. Thus, this type of finding supports that the improved survival using very low does of
chemotherapy concurrently with radiation is due to the radiosensitizing benefit of low-dose
chemotherapy on improving locoregional disease control (9, 10,11,14).
Full-dose chemotherapy can improve survival by targeting subclinical micrometastasis at its
earliest stage of cancer diagnosis. A regimen consisting of two cycles of full-dose induction
chemotherapy followed by chest radiotherapy has been common practice in many large
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clinical trials and has demonstrated prolongation of median survival times when compared
with radiation alone for locally advanced NSCLC (1,3,8). Similarly, concomitant
chemoradiotherapy using full-dose chemotherapeutic agents has been found superior to
radiotherapy alone in phase III studies for stage III NSCLC (18,19). Furthermore, when
concomitant chemoradiotherapy and induction chemotherapy were compared directly in
randomized phase III trials, the concomitant chemoradiation approach demonstrated better
survival outcome than induction chemotherapy followed by chest radiotherapy (2,4,20–23).
Unfortunately, the clinical gain from concomitant chemoradiation treatment has been
associated with higher rates of grade 3 and 4 toxicities during concurrent chemoradiation,
thus lowering treatment tolerability among many patients.
While the sequence of chemoradiotherapy appears to favor concurrent approach, there are
still unresolved issues related to sequence and dose intensity of chemotherapy and radiation.
The Cancer and Leukemia Group B (CALGB) published the first phase III trial to assess the
benefit of induction chemotherapy in the context of concomitant chemoradiotherapy for
stage III NSCLC (22). Both arms of the clinical study had concomitant chemoradiation, and
one of the two arms had induction chemotherapy. The result showed a trend in improving
median survival time favoring patients receiving induction chemotherapy followed by
concomitant chemoradiation. This trend disappeared when adjusted for weight loss
exceeding 5%. One major concern with the induction chemotherapy approach is that
delaying chest radiotherapy for 2–3 months during induction chemotherapy may adversely
affect local disease control and compromise ultimate treatment success. Chemotherapy alone
is known not effective for gross tumor control of NSCLC with an average response rate of
approximately 20% irrespective of the type of chemotherapy combinations for NSCLC (24).
Thus we question prolonged chemotherapy for 2–3 months in the induction phase and the
delay of starting radiotherapy may adversely affect the survival outcome. Indeed, in a study
of a cohort of 23 patients treated by prolonged induction chemotherapy (mean interval
before radiation treatment was 80.3 days for stage III NSCLC, it was found that 41% of
potentially curable patients became incurable during the chemotherapy period before the
start of radiation (15,16).
Our study design is a one-two punch approach by delivering only one cycle of induction
chemotherapy to target distant micrometastasis, which avoided delaying local therapy
beyond 4–6 weeks. The one-cycle chemotherapy targeted the subclinical disease at distant
sites, while the subsequent low-dose chemotherapy with concurrent radiation improves
radiation efficacy for gross tumors in the chest through radiosensitization, while minimizing
toxicities during chemoradiation by not using full-dose chemotherapy during radiation. Our
rationale and hypothesis is that distant microscopic cancer cells bear only minimal tumor
burden, thus one cycle of induction chemotherapy should suffice in eliminating the
potentially subclinical cancer cells, while allowing treatment of the chest disease sooner than
after the traditional 2–3 cycles of chemotherapy. Given the marrow suppressive potential of
cisplatin and docetaxel, the rh-GCSF treatment during the induction chemotherapy phase
has helped to avoid the unnecessary delay of chest radiotherapy from chemotherapy-induced
neutropenia. Our results showed no grade 3 or 4 neutropenia for delaying chest radiotherapy
after induction chemotherapy, likely due to rh-GCSF benefit.
Our survival data was very encouraging with a median overall survival of 32.6 months for
all patients enrolled with acceptable toxicity rates. While the 32.6 month median survival
seemed exceptionally good (25), it remained unclear if it was due to our unique study
design, potential skewed patient population in a pilot study, or if it was due to combination
docetaxel and cisplatin induction chemotherapy. Coincidentally, a study by Kocak et al also
reported exceptionally long median survival of 29.9 months for patients treated with
docetaxel (75 mg/m2) and cisplatin (75 mg/m2) induction chemotherapy followed by
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radiation with concurrent low-dose sensitizing docetaxel (30mg/m2) and cisplatin (20 mg/
m2), although the numbers of cycles differed between our study (1 cycle) and Kocak’s study
(3 cycles)(26). While two to four cycles of induction chemotherapy have been reported in
the literature for the treatment of locally advanced NSCLC, there is no literature evidence in
demonstrating the optimal number of cycles of induction chemotherapy. Theoretically,
longer periods of induction chemotherapy may allow for higher cumulative doses of
chemotherapy, while at risk for delaying local radiation treatment.
In conclusion, our trial results show that one-cycle full-dose docetaxel/cisplatin
chemotherapy with rh-GCSF followed by pulsed low-dose docetaxel chemoradiation is
associated with promising anti-tumor activity, resulting in encouraging survival outcome for
locally advanced NSCLC. We acknowledge the potential bias from a pilot study of 22
patients. We’d like to emphasize the translational nature of our study design, which was
based on the pre-clinical study and also on a novel hypothesis that one-cycle induction
chemotherapy should suffice for targeting distant subclinical disease. Given the promising
findings, this type of study design combining a shortened course of induction chemotherapy
with radiosensitizing chemoradiation should be considered for further investigation in larger
cohorts of patients. We are currently planning a follow-up study comparing the one cycle
induction chemotherapy with two cycles of induction chemotherapy and may be able to
demonstrate support for our hypothesis in the future.
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A representative radiation treatment plan from a patient who received conformal radiation
treatment for stage IIIa disease is demonstrated.
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Clonogenic survival of human lung cancer cell lines A549 (Figure 2a) and NCI-520 (Figure
2b) after irradiation at 2,4,6, and 8 Gy with sham irradiation as 0 Gy controls. The controls
(solid squares) are cells treated with irradiation without drug treatment. Survival cones were
scored for cell cultures treated with lower doses of docetaxel (25nM for A549, and 50nM for
NCI-520, solid circles and triangles) and followed by immediate radiation (3 h, circles)
versus delayed radiation (24 h, triangles). Likewise, survival cones were scored for cell
cultures treated with higher doses of docetaxel (50nM for A549, and 100nM for NCI-520,
empty circles and triangles) and followed by immediate radiation (3 h, circles) versus
delayed radiation (24 h, triangles). Each data point is generated by irradiated triplicate cell
cultures.
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Kaplan-Meier overall survival (solid black line), progression-free survival (dashed gray
line), and distant metastasis-free estimates (solid gray line) for patients in the clinical trial.
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Table 1
Patient Characteristics (n=22)




TNM Stage T1-4 N2M0 (IIIa) 9 (41%)
T1-3N3M0 (IIIb) 8 (36%)
TxN3M0 (IIIb) 2 (9%)
T4N1-2 (IIIb) 3 (14%)
Race White 19 (86%)
Black 2 (9%)
Asian 1 (5%)
Gender Male 15 (68%)
Female 7 (32%)
Age Median (range) 59 (41–76)
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Table 3
Grade 3 and 4 Toxicities
Toxicity*
Grade 3 Grade 4
Fatigue 18% (4/22) 0
Appetite Loss 18% (4/22) 0
Infection with normal ANC 23% (5/22) 0
Dyspnea/chest pain 9% (2/22) 0
Nausea/vomiting 27% (6/22) 0
Dysphagia/esophagitis 23% (5/22) 0
Headache 0 5% (1/22)
Lymphocytopenia 59% (13/22) 0
Allergic reaction 9% (2/22) 0
Bone pain (due to neupogen 0 5% (1/22)
*
Note: One grade 4 AV heart block (due to change in blood pressure medicine and an undiagnosed pre-existing cardiac condition)
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2012 August 1.
